Shopping Cart
Remove All
Your shopping cart is currently empty
Abciximab
😃Good
Catalog No. T76844Cas No. 143653-53-6
Alias C7E3
Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors.
Abciximab
Abciximab
😃Good
Catalog No. T76844Alias C7E3Cas No. 143653-53-6
Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $213 | In Stock | In Stock | |
| 5 mg | $563 | - | In Stock | |
| 10 mg | $886 | - | In Stock | |
| 25 mg | $1,330 | - | In Stock | |
| 50 mg | $1,780 | - | In Stock | |
| 100 mg | $2,430 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:95.5% (SDS-PAGE); 95.9% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors. |
| In vitro | Inhibiting platelet aggregation induced by physiologic and pathologic agonists, abciximab (C7E3) achieves this effect by binding to the platelet αIIbβ3 integrin[2]. Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them[2]. |
| In vivo | Effectively preventing neointimal hyperplasia, abciximab (C7E3) is administered at a dose of 0.25 mg/kg/day via intravenous infusion for 28 days[2]. |
| Synonyms | C7E3 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | glycoprotein (GP) IIb/IIIa |
| Molecular Weight | 95.18 kDa |
| Cas No. | 143653-53-6 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Fab-IgG1-CH1 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Abciximab | purchase Abciximab | Abciximab cost | order Abciximab | Abciximab in vivo | Abciximab in vitro | Abciximab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.